Legend Biotech's Breakthrough in Multiple Myeloma Study Prompts Positive Analyst Forecast
Portfolio Pulse from Vandana Singh
Legend Biotech announced positive results from the Phase 3 CARTITUDE-4 study, showing cilta-cel reduced the risk of disease progression or death by 74% in multiple myeloma patients. HC Wainwright analyst reiterated a Buy rating and increased the price target from $77 to $82.
June 06, 2023 | 7:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Legend Biotech's positive Phase 3 study results prompted HC Wainwright to reiterate a Buy rating and increase the price target from $77 to $82.
The positive results from Legend Biotech's Phase 3 CARTITUDE-4 study indicate a strong potential for cilta-cel in treating multiple myeloma patients. This has led HC Wainwright analyst to reiterate a Buy rating and increase the price target, which is likely to have a positive short-term impact on LEGN's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100